Status:
UNKNOWN
CBD Cigarettes Instead of Normal Cigarettes as Innovative Treatment for Schizophrenia
Lead Sponsor:
Psychiatric Hospital of the University of Basel
Conditions:
Schizophrenia and Other Psychotic Disorders
Harm Reduction
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Interventional study using Cannabidiol containing cigarettes as replacement of usual cigarettes Reduction of enforcement measures, improved acute treatment, harm reduction, and improvement of psychot...
Eligibility Criteria
Inclusion
- Diagnosis of Schizophrenia or Related Disorders
- PANNS \> 21,
- Tobacco-smokers
- inpatient status
- within age 18 - 65 years
- German-speaking
Exclusion
- personality disorder
- non-smokers
- organic psychotic diseases
- breast feeding
- pregnancy
Key Trial Info
Start Date :
October 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04700930
Start Date
October 4 2018
End Date
October 31 2021
Last Update
June 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitäre Psychiatrische Kliniken
Basel, Switzerland, 4002